An interventional study of BS, SPECT/CT, PET/CT, MRI in Bone Metastases, sponsored by Turku University Hospital. Completed at 1 site in Finland. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-02-28.
Sponsored by Turku University Hospital · Not applicable, Interventional, and Diagnostic
Prostate and breast cancer continues to be the most common cancer among men and women, respectively. The exact assessment of the cancer spread with detection of possible bone metastasis is crucial for treatment decision. In the current study 50 patients with prostate cancer and 50 patients with breast cancer at high risk for bone metastases or with know metastatic disease will be studied with multiple imaging modalities. Patients will be recruited from the Department of Oncology, Turku University Hospital. Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients. The primary objective is to determine the diagnostic accuracy of the four imaging modalities. The secondary goal is to calculate the sensitivities and specificities of the four imaging modalities on a patient-to-patient and lesion-to-lesion basis. Based on the results of this study an optimal imaging protocol for detection of prostate and breast cancer bone metastasis will be developed and validated.
3,517 studies on the registry are indexed under Neoplasm Metastasis; 883 are open to participants now.
This study's enrollment of 53 is close to the median of 54 across 2,765 interventional studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Turku University Hospital is the lead sponsor of 280 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Radiation: BS, SPECT/CT, PET/CT, MRI
Radiation: BS, SPECT/CT, PET/CT, MRI
Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
Number of participants with bone metastases
Time frame: at least 6 months follow up
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Turku University Hospital